Drug intelligence / Profile preview

HL217

Development stage: Unknown
Lead developer: Hanlim Pharm. Co., Ltd.
Modality: Small Molecules
Administration: Oral

Overview

HL217 is an investigational small molecule developed by Hanlim Pharm for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). As a non-stimulant therapeutic candidate, HL217 is designed to modulate neurotransmitter levels in the brain to improve focus and reduce impulsivity without the risk of dependency often associated with stimulant-based treatments. The drug is currently in Phase 2 clinical development, primarily targeting the South Korean market as a potential alternative to existing ADHD medications.

Targets

NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on HL217.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HL217.

Explore the full profile